BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19893039)

  • 1. Novel biomarkers for prostate cancer including noncoding transcripts.
    Romanuik TL; Ueda T; Le N; Haile S; Yong TM; Thomson T; Vessella RL; Sadar MD
    Am J Pathol; 2009 Dec; 175(6):2264-76. PubMed ID: 19893039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction.
    Pinzani P; Lind K; Malentacchi F; Nesi G; Salvianti F; Villari D; Kubista M; Pazzagli M; Orlando C
    Hum Pathol; 2008 Oct; 39(10):1474-82. PubMed ID: 18619642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
    Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
    Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
    Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
    Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma.
    Cho-Vega JH; Tsavachidis S; Do KA; Nakagawa J; Medeiros LJ; McDonnell TJ
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2615-22. PubMed ID: 18086765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype.
    Whitaker HC; Shiong LL; Kay JD; Grönberg H; Warren AY; Seipel A; Wiklund F; Thomas B; Wiklund P; Miller JL; Menon S; Ramos-Montoya A; Vowler SL; Massie C; Egevad L; Neal DE
    Oncogene; 2014 Nov; 33(45):5274-87. PubMed ID: 24240687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.
    Gregg JL; Brown KE; Mintz EM; Piontkivska H; Fraizer GC
    BMC Cancer; 2010 Apr; 10():165. PubMed ID: 20426842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer-associated gene expression alterations determined from needle biopsies.
    Qian DZ; Huang CY; O'Brien CA; Coleman IM; Garzotto M; True LD; Higano CS; Vessella R; Lange PH; Nelson PS; Beer TM
    Clin Cancer Res; 2009 May; 15(9):3135-42. PubMed ID: 19366833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
    Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
    J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
    Chakrabarti R; Robles LD; Gibson J; Muroski M
    Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
    Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
    Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.
    Heemers HV; Schmidt LJ; Sun Z; Regan KM; Anderson SK; Duncan K; Wang D; Liu S; Ballman KV; Tindall DJ
    Cancer Res; 2011 Mar; 71(5):1978-88. PubMed ID: 21324924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
    Piao XM; Byun YJ; Jeong P; Ha YS; Yoo ES; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
    Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
    Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
    Knight JF; Shepherd CJ; Rizzo S; Brewer D; Jhavar S; Dodson AR; Cooper CS; Eeles R; Falconer A; Kovacs G; Garrett MD; Norman AR; Shipley J; Hudson DL
    Br J Cancer; 2008 Dec; 99(11):1849-58. PubMed ID: 19002168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative expression profile of PSGR in prostate cancer.
    Xu LL; Sun C; Petrovics G; Makarem M; Furusato B; Zhang W; Sesterhenn IA; McLeod DG; Sun L; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2006; 9(1):56-61. PubMed ID: 16231015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags.
    Asmann YW; Kosari F; Wang K; Cheville JC; Vasmatzis G
    Cancer Res; 2002 Jun; 62(11):3308-14. PubMed ID: 12036949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.